In present study, a series of 3-[(5-methyl-1,3-benzoxazol-2-yl)amino]-2-phenyl-2,3-dihydro-4H-1,3-
benzothiazin-4-ones (6a-n) were synthesized and elucidated by elemental, FT-IR, 1H & 13C NMR and
LC-MS studies. The in vitro antibacterial screening against Gram-positive bacterial strains such as B.
subtilis, S. aureus, S. epidermidis and Gram-negative bacteria such as E. coli, P. aeruginosa was
carried in comparison with tetracycline as reference standard. Antifungal activities against different
fungal strains namely R. oryzae, A. niger, A. favus, C. albicans and S. cerevisiae have been evaluated
by comparing with fluconazole as reference standard. Compounds 6b, 6c, 6e, 6j, 6m and 6n emerged
as highly potent antimicrobial agents. The DPPH radical scavenging assay of the synthesized moieties
showed good antioxidant potency comparable to standard ascorbic acid. The molecular docking
simulation studies of all the title compounds in their active conformation analogues with target proteins
(PDB ID 2XCT-antibacterial, PDB ID 1IYL-antifungal, PDB ID 2HCK- antioxidant) exhibited good
binding interactions in top scoring poses. The pharmacokinetic properties prediction by ADMET
descriptors and Lipinski′s rule of five endorse the properties of newly synthesized compounds to a
drug molecule. The results of the docking protocols were compatible with the in vitro studies which
validates the potency of the molecules.